Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,050 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 3 Interventional

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

NCT00331487
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Rosiglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
67
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

NCT02366312
View directory record Official record
Conditions
Keratocystic Odontogenic Tumor
Interventions
vismodegib
Drug
Lead sponsor
NYU College of Dentistry
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 1 Interventional

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

NCT02278965
View directory record Official record
Conditions
Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions
Metformin, Omega-3 fatty acids
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 28, 2026, 8:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

NCT06029309
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Zanubrutinib, Tafasitamab
Drug
Lead sponsor
Alvaro Alencar, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 8:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC)
Interventions
Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

NCT01889238
View directory record Official record
Conditions
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
95
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Lone Tree, Colorado + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 4 Interventional

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

NCT01889758
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 28, 2026, 8:34 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

NCT05913752
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
CMND-100
Drug
Lead sponsor
Clearmind Medicine Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 8:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

NCT02372799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 2 Interventional Results available

AZD7268 Safety and Tolerability Study

NCT01020799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD7268, Escitalopram, Placebo capsules, Placebo tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

NCT01283516
View directory record Official record
Conditions
Tumors Characterized by Genetic Abnormalities of ALK
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 28, 2026, 8:34 PM EDT
Terminated Phase 2 Interventional Results available

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

NCT05516498
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

NCT07193563
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
ENX-102, Placebo
Drug · Other
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 8:34 PM EDT
Terminated Not applicable Interventional

PB125, Osteoarthritis, Pain, Mobility, and Energetics

NCT04638387
View directory record Official record
Conditions
Osteoarthritis, Knee, Muscle Weakness, Pain, Joint
Interventions
PB125, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
50 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 28, 2026, 8:34 PM EDT
Withdrawn Early Phase 1 Interventional

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

NCT04570449
View directory record Official record
Conditions
Covid19
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

NCT00302458
View directory record Official record
Conditions
Healthy
Interventions
OROS-Methylphenidate, Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 28, 2026, 8:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluating the Effects of a Synbiotic Versus Probiotic or Placebo on Gut Microbiota and Cardiometabolic Health: A Randomized Double-Blind Placebo Controlled Trial

NCT06544915
View directory record Official record
Conditions
Blood Pressure, Body Composition, Immune Function
Interventions
Synbiotic, Probiotic, Placebo
Dietary Supplement
Lead sponsor
Skidmore College
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 28, 2026, 8:34 PM EDT
Not listed Phase 2 Interventional

Efficacy of Celecoxib 200mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee

NCT00597415
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
celecoxib, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2008 · Synced Oct 28, 2026, 8:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

NCT01894581
View directory record Official record
Conditions
Obesity, Fertility
Interventions
LOVAZA, GnRH
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 28, 2026, 8:34 PM EDT